Imagine losing your vision due to an aggressive yet often overlooked fungal infection inside the eye—that's a harsh reality for many patients worldwide, particularly in South and Southeast Asia where such infections are more common. But here’s where it gets controversial: unlike bacterial eye infections, fungal endophthalmitis lacks universally accepted diagnostic or treatment protocols. The rarity of the condition, its variable clinical signs, and limited rigorous research make it a complex challenge for ophthalmologists. Delay or misdiagnosis can lead to irreversible blindness, a tragedy that underscores the urgent need for clear, standardized guidelines. Plus, with fungi increasingly developing resistance to antifungal drugs and no standardized testing methods in place, clinicians face an uphill battle in managing these cases effectively.
Recognizing this critical gap, a coalition of leading eye health organizations in the Asia-Pacific—namely the Asia-Pacific Vitreo-Retina Society (APVRS), the Academy of the Asia-Pacific Professors of Ophthalmology (AAPPO), and the Asia-Pacific Society of Ocular Inflammation and Infection (APSOII)—set out to create a comprehensive set of recommendations. In October 2025, they published a groundbreaking consensus document featuring 20 carefully crafted statements. These were developed by 24 experts from a dozen countries, carefully analyzing decades of clinical experience and research to unify approaches across the region. This initiative marked the first time a region-wide consensus on fungal endophthalmitis was established, offering invaluable guidance on early diagnosis, treatment strategies, surgical interventions, and even the role of corticosteroids—an area with contentious opinions.
The collaborative effort, led by Professors Taraprasad Das and Dennis S. C. Lam, covered five critical areas: understanding the disease, diagnosing it accurately, grasping its biological mechanisms, managing treatment, and exploring future directions. Key points of agreement include: fungal infections tend to manifest later than bacterial ones, with Aspergillus, Candida, and Fusarium being the most common culprits. Patients with weakened immune systems are especially vulnerable. The experts strongly recommend early vitrectomy surgery to reduce fungal load and improve medication penetration. They also advocate for combined antifungal therapy—administered via the eye, systemically, and topically—for the best potential results.
Advanced molecular diagnostic tools such as PCR (polymerase chain reaction), next-generation sequencing (NGS), and MALDI-TOF are recognized as game-changers, especially for cases where traditional cultures come up empty. Interestingly, opinions are divided regarding corticosteroids, with only a quarter of the panel supporting their use directly inside the eye due to potential immune suppression risks—highlighting a debate that will continue to evolve.
Looking ahead, these guidelines emphasize continued antimicrobial stewardship, the use of rapid biomarker tests like 1,3 β-D-glucan and galactomannan for faster detection, and experimenting with new drugs such as olorofim and terbinafine to combat resistant fungal strains. Despite its often underreported and underestimated prevalence, fungal endophthalmitis can severely impair vision or cause blindness if not caught early. This consensus offers a practical framework for clinicians: prioritize swift diagnosis, tailor antifungal therapy precisely, consider timely surgical intervention carefully, and stay updated with emerging diagnostic and treatment innovations.
This international agreement also serves a vital purpose for regions with limited resources. Standardized diagnostic criteria and treatment protocols simplify decision-making processes for ophthalmologists managing these complicated infections. The integration of molecular diagnostics and stewardship programs aims to catch infections sooner and curb the development of resistance. Moreover, unifying efforts globally, especially on emerging threats like Candida auris, is essential for future preparedness. Ultimately, these guidelines pave the way for larger-scale research and multicenter clinical trials, promising improved outcomes and hopefully saving more patients' sight in the future.
Source:
Journal reference:
Das, T., et al. (2025). International consensuses and guidelines on diagnosing and managing fungal endophthalmitis by the Asia-Pacific Vitreo-retina Society (APVRS), the Academy of the Asia-Pacific Professors of Ophthalmology (AAPPO), and the Asia-Pacific Society of Ocular Inflammation and Infection (APSOII). Eye and Vision. doi: 10.1186/s40662-025-00456-y. https://link.springer.com/article/10.1186/s40662-025-00456-y
